uploads/2018/09/Chart-003-Market-Cap-1.jpg

A Look at the Market Caps of the Pharma Stocks under Review

By

Updated

Pharma stocks

As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

The chart above compares the market caps of these companies.

Article continues below advertisement

Eli Lilly

Eli Lilly and Company is one of the leading US pharmaceutical companies, and its product portfolio includes both human pharmaceutical products and animal health products. Eli Lilly’s market cap is ~$114.5 billion as of September 14.

Pfizer

Pfizer’s product portfolio is divided into two segments: Innovative Health and Essential Health. Pfizer’s market cap is ~$251.2 billion as of September 14.

Article continues below advertisement

Merck & Co.

Merck & Co. is divided into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck & Co.’s market cap is ~$188.4 billion as of September 14.

Allergan

Allergan deals with both generic and specialty pharmaceutical products. Allergan has classified its business into three segments: US General Medicines, US Specialized Therapeutics, and International Business. Allergan’s market cap is ~$64.5 billion as of September 14.

GlaxoSmithKline

GlaxoSmithKline, a British multinational pharmaceutical company, has classified its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline stock is listed on the London Stock Exchange. The company’s market cap is ~73.8 billion British pounds as of September 14, and the market cap for its ADR (American depositary receipt) is ~$96.8 billion as of the same date.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 5.2% of its total investments in Eli Lilly, 5.2% in Merck & Co., 5.4% in Pfizer, and 4.7% in GlaxoSmithKline.

Advertisement

More From Market Realist